Phase ll study of Panitumumab for advanced colorectal cancer which has prior therapy of Bevacizumab

ABSTRACT: Interventions: FOLFOX+Panitumumab repeat every 14 days until discontinuance criteria. FOLFIRI+Panitumumab repeat every 14 days until discontinuance criteria. Primary outcome(s): Response Rate:RR Study Design: Parallel Non-randomized

DISEASE(S): Metastatic Colorectal Cancer

PROVIDER: 2620619 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR